Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
about
Systemic delivery to central nervous system by engineered PLGA nanoparticlesPromising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.Peptides and proteins used to enhance gold nanoparticle delivery to the brain: preclinical approachesGetting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrierCentral nervous system toxicity of metallic nanoparticlesTargeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage DisordersNanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.The potential of magneto-electric nanocarriers for drug deliveryDrug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of gliomaDrug delivery systems, CNS protection, and the blood brain barrierInhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation.Surface chemistry governs cellular tropism of nanoparticles in the brain.Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier.Anti-inflammatory peptides from cardiac progenitors ameliorate dysfunction after myocardial infarctionHuman serum albumin-based nanoparticle-mediated in vitro gene deliveryOpen challenges in magnetic drug targetingEndocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles.Novel treatment strategies for brain tumors and metastases.Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma.Click synthesis of a polyamidoamine dendrimer-based camptothecin prodrug.Bidirectional Transfer Study of Polystyrene Nanoparticles across the Placental Barrier in an ex Vivo Human Placental Perfusion Model.A critical evaluation of drug delivery from ligand modified nanoparticles: Confounding small molecule distribution and efficacy in the central nervous system.Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles.Systemic delivery of blood-brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissueThe Antidepressant Effect of L-Tyrosine-Loaded Nanoparticles: Behavioral Aspects.Diverse Applications of Nanomedicine.Methods for the In Vitro Characterization of Nanomedicines-Biological Component Interaction.Novel drug-delivery approaches to the blood-brain barrier.Influence of chronobiology on the nanoparticle-mediated drug uptake into the brain.Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.The Use of Anthracyclines for Therapy of CNS Tumors.Smart Polymeric Nanoparticles as Emerging Tools for Imaging--The Parallel Evolution of Materials.Strategies for transporting nanoparticles across the blood-brain barrier.Nanomedicine and nanotoxicology: the pros and cons for neurodegeneration and brain cancer.Targeting specific cells in the brain with nanomedicines for CNS therapiesVectorized nanodelivery systems for ischemic stroke: a concept and a need.Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells.Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
P2860
Q26751294-442D8B17-1DC2-425E-8616-A5DB724B4593Q26778701-62346EBB-DF39-43AC-9485-EDC31D952F82Q26795570-C9062603-A2B1-4072-B309-74A34B0444D5Q28071873-060C4A4D-C9C9-4E83-986D-004A1122D1BAQ28084729-03BDD814-7A6C-4E49-922D-51C3D5B4D584Q28552459-EE4B7E88-3FDE-4916-B210-B7AD62591D05Q30354652-0ADD1272-4F59-4F50-BA82-506254C41183Q30403718-F6D84CEB-6D2F-4196-9F27-84FBADE762E5Q30413487-A267E94E-3B1A-469D-AF54-686921776559Q30432845-62E9DCD1-1A92-4142-979C-8F205F20E982Q30849102-BD5E1355-2937-47F3-9A6F-772EF4EB62BEQ30854434-1B23104F-C1DF-4139-909B-B024B438B935Q35034401-D5C78D1A-4FD9-4180-9D2C-79CD55BEAB99Q35114912-0057D38A-CA51-45C6-A065-27562C05690AQ35258046-EFBAF548-E66A-4BED-8BFA-D0D9B81A4DF8Q35417351-5707033D-8404-4830-A96F-51AE50816CF5Q35671789-4194913B-7100-4906-B808-E77956184F4AQ35734471-77BFB427-1444-4AF3-B4AD-603E1FA276AFQ36031889-57823574-A86F-4F72-B969-6372E0F771B6Q36345289-5D8F01A5-2FB2-44FA-AFFD-E341E3AAA1D3Q36350868-1D4A2873-9107-4CDD-9550-B369FD5EA3B9Q36396207-9E7036AD-96E9-44DD-A89E-335EA4FE631CQ36443038-6BE3ABAF-EF9B-45E7-BFB5-1CF0F343A482Q36881132-BEE4357F-74D9-42A4-AF6A-0576BA6C986FQ37251107-1A1161AC-3DF7-4ACD-B96B-F7E02E97CC98Q37728142-C8E0CA07-346D-4FB0-AA20-907672DBE8EFQ37731267-4DFD5F0C-44A8-4370-87BE-ACD12FB9FC29Q38321195-24D33476-6109-4D99-ABDF-DE722E0CF6D2Q38345205-F10BE5C5-82A4-45A0-8274-033BFCB48058Q38351134-42E17FCF-3192-47D1-B823-F56B91899607Q38407992-C325DDBF-E1FD-48BB-9A72-54867B9D29E6Q38632193-1CEA3BB5-AEF1-4C04-8AF1-500519073FDEQ38662677-F43EC927-6108-4028-BD1E-7BCCE2DE890AQ38665015-53E6B574-D178-4818-BBE7-EAF95EC6BF58Q38674279-C37E2777-F907-4D69-A643-CFA47095AE70Q38731765-98AFEB4E-BB26-42A7-B00F-8FE89E92B56BQ38761724-3C1C1378-2754-4B7C-B850-E2AADAA97B7AQ38765826-057D3D18-6082-4669-BD3E-207B8001DB30Q38792519-B84B1D9C-952B-4C3E-8682-99FF1A6D9361Q38808008-DB3761A4-13D2-4169-87D0-2606C693E1EB
P2860
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
@ast
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
@en
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
@nl
type
label
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
@ast
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
@en
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
@nl
prefLabel
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
@ast
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
@en
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
@nl
P1476
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
@en
P2093
Jörg Kreuter
P356
10.1016/J.ADDR.2013.08.008
P407
P577
2013-08-24T00:00:00Z